A Study to Evaluate FK778 in Kidney Transplant Patients
NCT ID: NCT00189735
Last Updated: 2008-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
364 participants
INTERVENTIONAL
2003-09-30
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation
NCT00189839
A Study to Evaluate the Safety and Effectiveness of FK778 in Liver Transplant Patients
NCT00451932
Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy
NCT00104338
Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation
NCT00717379
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients
NCT00384137
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FK778
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has been fully informed.
Exclusion Criteria
* Patient has significant liver disease.
* Cold ischemia time of the donor kidney \>28 hours.
* Patient having uncontrolled concomitant infections and/or severe diarrhoea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer.
* Patient has previously received or is receiving an organ transplant other than kidney.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe B.V.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
H. H. Neumayer
Role: PRINCIPAL_INVESTIGATOR
Universitätsklinik Charité
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Innsbruck, , Austria
Brussels, , Belgium
Brussels, , Belgium
Leuven, , Belgium
Prague, , Czechia
Brest, , France
Créteil, , France
Grenoble, , France
Le Kremlin-Bicêtre, , France
Montpellier, , France
Rennes, , France
Saint-Etienne, , France
Toulouse, , France
Berlin, , Germany
Berlin, , Germany
Essen, , Germany
Frankfurt, , Germany
Halle, , Germany
München, , Germany
Regensburg, , Germany
Padua, , Italy
Roma, , Italy
Torino, , Italy
Maastricht, , Netherlands
Bydgoszcz, , Poland
Szczecin, , Poland
Barcelona, , Spain
Barcelona, , Spain
Barcelona, , Spain
Córdoba, , Spain
Madrid, , Spain
Madrid, , Spain
Santander, , Spain
Valencia, , Spain
Uppsala, , Sweden
Zurich, , Switzerland
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FG-778-02-60
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.